Literature DB >> 8521409

Interleukin-1 beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells.

S Kondo1, B P Barna, T Morimura, J Takeuchi, J Yuan, A Akbasak, G H Barnett.   

Abstract

Increasing the susceptibility of tumor cells to apoptotic cell death following chemotherapy is of importance to the outcome of cancer treatment. Although the tumor suppressor gene p53 is required for efficient induction of apoptosis by chemotherapeutic agents, it is not the only apoptosis mediator gene. The molecular mechanisms mediating apoptosis following chemotherapy via p53-dependent or p53-independent pathways remain unclear. We show here that cis-diamminedichloroplatinum (cisplatin) induces the expression of interleukin-1 beta-converting enzyme (ICE), a mammalian homologue of the Caenorhabditis elegans cell death gene ced-3, in murine and human malignant glioma cells during apoptosis regardless of their p53 status. Furthermore, overexpression of the murine ICE gene induces apoptosis in these tumor cells. The apoptosis induced by cisplatin treatment or murine ICE overexpression can be suppressed by the tetrapeptide ICE inhibitor Ac-YVAD-CMK or the apoptosis inhibitors bcl-2 or bcl-2-related bcl-XL gene. These findings suggest that ICE may mediate apoptosis induced by chemotherapy, and its induction could represent a novel approach for the effective treatment of malignant glioma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521409

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  A functional role for death proteases in s-Myc- and c-Myc-mediated apoptosis.

Authors:  S Kagaya; C Kitanaka; K Noguchi; T Mochizuki; A Sugiyama; A Asai; N Yasuhara; Y Eguchi; Y Tsujimoto; Y Kuchino
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

2.  Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.

Authors:  Hideaki Ito; Takao Kanzawa; Toru Miyoshi; Satoshi Hirohata; Satoru Kyo; Arifumi Iwamaru; Hiroshi Aoki; Yasuko Kondo; Seiji Kondo
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

3.  Expression of IL 1betaconverting enzyme in 5-FU induced apoptosis in esophageal carcinoma cells.

Authors:  Li-Ying Deng; Yun-Han Zhang; Ping Xu; Su-Min Yang; Xue-Bin Yuan
Journal:  World J Gastroenterol       Date:  1999-02       Impact factor: 5.742

Review 4.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

5.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.

Authors:  M Nagane; A Levitzki; A Gazit; W K Cavenee; H J Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  Optimized mixture of As, Cd and Pb induce mitochondria-mediated apoptosis in C6-glioma via astroglial activation, inflammation and P38-MAPK.

Authors:  Weiming He; Yingfu Li; Jingyan Tian; Ning Jiang; Bo Du; Yuping Peng
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

7.  The p42 variant of ETS1 protein rescues defective Fas-induced apoptosis in colon carcinoma cells.

Authors:  R Li; H Pei; T Papas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

8.  Caspase-1 is a direct target gene of ETS1 and plays a role in ETS1-induced apoptosis.

Authors:  Huiping Pei; Chunyang Li; Yair Adereth; Tien Hsu; Dennis K Watson; Runzhao Li
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

9.  The prosurvival role of autophagy in Resveratrol-induced cytotoxicity in human U251 glioma cells.

Authors:  Jun Li; Zhenghong Qin; Zhongqin Liang
Journal:  BMC Cancer       Date:  2009-06-30       Impact factor: 4.430

10.  Caspase 1 involvement in human monocyte lysis induced by Actinobacillus actinomycetemcomitans leukotoxin.

Authors:  P Kelk; A Johansson; R Claesson; L Hänström; S Kalfas
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.